Severe irinotecan-induced toxicity in a patient with UGT1A1*28 and UGT1A1*6 polymorphisms

Table 1 Area under the curve of irinotecan, SN-38 and SN-38G for this patient at various doses of irinotecan, compared with a group of patients with wild type UGT1A1 at the standard dose of irinotecan

Irinotecan dose (mg/m2)	AUCirinotecan (ng/mL per hour)	AUCSN-38 (ng/mL per hour)	AUCSN-38G (ng/mL per hour)	AUCSN-38G/AUCSN38
180	26838	929	3000	3.2
90	12790	476	2014	4.2
54	9488	328	2096	3.4
UGT1A1 wild type patients1
180	6321 ± 3993	234 ± 185	645 ± 353	3.3 ± 2.1

¹Treated with standard FOLFIRI regimen at our cancer center (n = 38, mean ± SD). AUC: Area under the curve.